Table 1. Characteristics of all Eligible Orthotopic Liver Transplant Recipients and Donors in the Study (N=307).
| Variable | |
|---|---|
| Age (median, IQR) | |
| Recipient | 51 (41-56) |
| Donor | 46 (34-55) |
| Gender donor/recipient, N (%) | |
| Male/male | 105 (34.2) |
| Male/female | 52 (16.9) |
| Female/male | 85 (27.7) |
| Female/female | 65 (21.2) |
| Primary liver disease, N (%) | |
| Viral | 59 (19.2) |
| Alcoholic | 46 (15.0) |
| Cholestatic | 79 (25.7) |
| Other disease§ | 123 (40.1) |
| Child-Pugh class, N (%) | |
| A | 67 (21.8) |
| B | 138 (45.0) |
| C | 102 (33.2) |
| Lab MELD score (median, IQR) | 15 (11-21) |
| Donor-type, N (%) | |
| Donation after cardiac death | 24 (7.8) |
| Donation after brain death | 283 (92.2) |
| Maintenance immunosuppression, N (%) | |
| Prednisone / CNI / basiliximab (+ MMF) | 206 (67.1) |
| Prednisone / CNI (+ azathioprine) | 101 (32.9) |
| Acute cellular rejection, N (%) | |
| Yes | 107 (34.9) |
| No | 200 (65.1) |
| Bacterial infection, N (%) | 94 (30.6) |
| LCBI | 52 (55.3) |
| PNEU | 10 (10.6) |
| IAB | 32 (34.0) |
IQR denotes interquartile range; MELD, Model for End-Stage Liver Disease; CNI, calcineurin inhibitors; MMF, mycophenolate mofetil; LCBI, laboratory-confirmed bloodstream infection; PNEU, pneumonia; IAB, intra-abdominal infection.
§ Other diseases included predominately autoimmune hepatitis, cryptogenic cirrhosis and metabolic disorders.